| Name | Title | Contact Details |
|---|
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
DURECT Corporation is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modern Medical Systems is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Barnett and Ramel Optical is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform. The Company`s CellFX NPS platform provides a novel, precise, non-thermal, treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing acellular tissue. NPS`s unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane initiating a cascade of events within the cell that results in regulated cell death.